TITLE

O-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

AUTHOR(S)
Jiang, Xiaoyin; Reardon, David; Desjardins, Annick; Vredenburgh, James; Quinn, Jennifer; Austin, Alan; Herndon, James; McLendon, Roger; Friedman, Henry
PUB. DATE
August 2013
SOURCE
Journal of Neuro-Oncology;Aug2013, Vol. 114 Issue 1, p135
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized that MGMT immunohistochemistry would predict resistance to temozolomide in PCNSL. A retrospective study of newly-diagnosed and recurrent PCNSL patients treated at our institution was conducted to study the predictive value of MGMT immunohistochemistry for response to temozolomide. 20 patients who were treated with temozolomide as a single agent were identified during the study time period. 6/20 patients demonstrated a response, corresponding to an objective response rate of 30 % (95 % CI 8-52). Five patients with low MGMT level (<30 %) showed a response to temozolomide. Only one of 10 patients (10 %) with high MGMT level (≥30 %) exhibited a response to temozolomide. Small sample numbers precluded formal statistical comparisons. Two patients with complete response remain alive without progressive disease 6.7 and 7.2 years after temozolomide initiation. Immunohistochemistry can be performed on small biopsies to selectively assess MGMT status in tumor versus surrounding inflammation. MGMT analysis by immunohistochemistry may predict response to temozolomide in PCNSL and should be prospectively investigated.
ACCESSION #
89411839

 

Related Articles

  • Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. Seung-Ho Yang; Kun Lee; Il Kim; Jae Hong; Jae Sung; Byung Son; Sang Lee; Yong-Kil Hong // Journal of Neuro-Oncology;Mar2009, Vol. 92 Issue 1, p65 

    Abstract  We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m2 for induction and at a...

  • The Complexities of Resistance to Bevacizumab. Shen, Han; McDonald, Kerrie L. // Journal of Cancer Therapy;Oct2012, Vol. 3 Issue 5, p491 

    Glioblastoma is a highly malignant primary tumor of the central nervous system tumor with a poor survival rate. The treatment of glioblastoma is shifting from a purely cytotoxic approach to one that incorporates anti-angiogenic agents. Bevacizumab (Avastin®; Roche) was approved in the United...

  • Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye. Myung-Chul Kim; D'Costa, Susan; Suter, Steven; Yongbaek Kim // Journal of Veterinary Science;2014, Vol. 15 Issue 2, p481 

    Cancer stem cell (CSC) research has increased exponentially to gain further insight into the mechanisms underlying both carcinogenesis and chemotherapy resistance. The present study was performed to explore the potential value of a side population (SP) assay for identifying and characterizing...

  • cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. Manfè, Valentina; Biskup, Edyta; Willumsgaard, Ayalah; Skov, Anne Guldhammer; Palmieri, Dario; Gasparini, Pierluigi; Laganá, Alessandro; Woetmann, Anders; Ødum, Niels; Croce, Carlo Maria; Gniadecki, Robert // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Successful/effective cancer therapy in low grade lymphoma is often hampered by cell resistance to anti-neoplastic agents. The crucial mechanisms responsible for this phenomenon are poorly understood. Overcoming resistance of tumor cells to anticancer agents, such as proteasome inhibitors, could...

  • Isolation and characterization of tumor stem-like cells from human meningiomas. Hueng, Dueng-Yuan; Sytwu, Huey-Kang; Huang, Shih-Ming; Chang, Chen; Ma, Hsin-I // Journal of Neuro-Oncology;Aug2011, Vol. 104 Issue 1, p45 

    Recent advances in research have found that tumor stem-like cells are resistant to surgery, radiotherapy, and chemotherapy. Tumor stem-like cells play critical roles in tumor recurrence, angiogenesis, and invasion in malignant brain tumors. However, the identification of tumor stem-like cells in...

  • Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 - a single centre report. Jezersek Novakovic, Barbara // Radiology & Oncology;2012, Vol. 46 Issue 4, p346 

    Background. Primary central nervous system lymphomas (PCNSL) are rare variants of extranodal non-Hodgkin′s lymphomas that are nowadays primarily treated with high-dose methotrexate or methotrexate-based chemotherapy with or without radiation therapy. The optimal treatment of PCNSL is still...

  • Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D3 display increased CDK2 and CDK6 activity and shortened G1 phase. Wang, Qing Mei; Luo, Xun; Kheir, Ahmed; Coffman, Frederick D; Studzinski, George P // Oncogene;5/28/98, Vol. 16 Issue 21, p2729 

    Drug resistance that occurs during cancer chemotherapy has been a major problem in controlling neoplastic progression. To study the cellular mechanisms of acquired drug resistance we developed 1,25-dihydroxyvitamin D3 (1,25D3)-resistant sublines of promyelocytic leukemia HL60 cells which have...

  • Drug strikes tumors other treatments miss.  // USA Today Magazine;Feb96, Vol. 124 Issue 2609, p8 

    Reports on the testing of a novel anti-cancer drug called tirapazamine that strikes only those tumor cells that resist standard treatments. Lethal effect on cells with very low concentrations of oxygen; Role of hypoxia in drug resistance; Controllability of drug's side effects.

  • Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Toyokawa, Gouji; Seto, Takashi; Takenoyama, Mitsuhiro; Ichinose, Yukito // Cancer & Metastasis Reviews;Dec2015, Vol. 34 Issue 4, p797 

    Anaplastic lymphoma kinase ( ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics